Sign in

Private company

Celyad Oncology SA

Pharmaceutical preparations company1

In its 2023 annual report (Form 20-F) the company says: “We are a limited liability company incorporated in the form of a naamloze vennootschap/société anonyme under Belgian law. We are registered with the Register of Legal Entities (RPM Nivelles) under the enterprise number 891.118.115. Our agent for service of process in the United States is Celyad Inc., World Financial District, 60 Broad Street, Suite 3502, New York, NY 10004.”10

Last updated Oct 21, 2026.

Overview

0Revenue, fiscal 20222
-40.9MNet income, fiscal 20222
  • IndustryPharmaceutical Preparations1
  • HeadquartersC91
  • Incorporated inBelgium3
  • Business addressRue Edouard Belin 12, Mont-Saint-Guibert, C9 14353
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2022

-948.2%Return on equity2
0.00×Debt to equity2
-28.1M EURFree cash flow2

Financial statements

Revenue4567820 EUR in 2022
05.0M EUR10.0M EUR15.0M EUR2015: 3.0K EUR3.0K EUR20152016: 10.0M EUR10.0M EUR2016+333633%2017: 3.5M EUR3.5M EUR2017−65%2018: 3.1M EUR3.1M EUR2018−12%2019: 6.0K EUR6.0K EUR2019−100%2020: 5.0K EUR5.0K EUR2020−17%2021: 0 EUR0 EUR20212022: 0 EUR0 EUR2022
Gross profit4567820 EUR in 2022
02.5M EUR5.0M EUR7.5M EUR10.0M EUR2015: 1.0K EUR1.0K EUR20152016: 8.5M EUR8.5M EUR2016+847000%2017: 3.0M EUR3.0M EUR2017−64%2018: 3.1M EUR3.1M EUR2018+3%2019: 6.0K EUR6.0K EUR2019−100%2020: 5.0K EUR5.0K EUR2020−17%2021: 0 EUR0 EUR20212022: 0 EUR0 EUR2022
Operating income56782-40.9M EUR in 2022+60% since 2016
-60.0M EUR-40.0M EUR-20.0M EUR02016: -25.6M EUR-25.6M EUR20162017: -52.9M EUR-52.9M EUR2017+106%2018: -38.2M EUR-38.2M EUR2018−28%2019: -28.9M EUR-28.9M EUR2019−24%2020: -17.0M EUR-17.0M EUR2020−41%2021: -26.4M EUR-26.4M EUR2021+55%2022: -40.9M EUR-40.9M EUR2022+55%
Net income456782-40.9M EUR in 2022+41% since 2015
-60.0M EUR-40.0M EUR-20.0M EUR02015: -29.1M EUR-29.1M EUR20152016: -23.6M EUR-23.6M EUR2016−19%2017: -56.4M EUR-56.4M EUR2017+139%2018: -37.4M EUR-37.4M EUR2018−34%2019: -28.6M EUR-28.6M EUR2019−23%2020: -17.2M EUR-17.2M EUR2020−40%2021: -26.5M EUR-26.5M EUR2021+54%2022: -40.9M EUR-40.9M EUR2022+54%
Fiscal year20152016201720182019202020212022
Revenue3.0K EUR410.0M EUR53.5M EUR63.1M EUR76.0K EUR85.0K EUR20 EUR20 EUR2
Gross profit1.0K EUR48.5M EUR53.0M EUR63.1M EUR76.0K EUR85.0K EUR20 EUR20 EUR2
Research and development20.8M EUR218.9M EUR2
Selling, general and admin9.9M EUR210.5M EUR2
Operating income-25.6M EUR5-52.9M EUR6-38.2M EUR7-28.9M EUR8-17.0M EUR2-26.4M EUR2-40.9M EUR2
Interest255.0K EUR2198.0K EUR2
Income before tax-26.5M EUR2-40.9M EUR2
Income tax10.0K EUR265.0K EUR2
Net income-29.1M EUR4-23.6M EUR5-56.4M EUR6-37.4M EUR7-28.6M EUR8-17.2M EUR2-26.5M EUR2-40.9M EUR2
Earnings per share-3.4K EUR/shares4-2.5K EUR/shares5-6 EUR/shares6-3 EUR/shares7-2 EUR/shares8-1 EUR/shares2-2 EUR/shares2-2 EUR/shares2
Shares (weighted, basic)15.6M shares222.6M shares2

Compare Celyad Oncology SA with another company

Corporate structure

Celyad Oncology SA sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Celyad Oncology SA

  • Celyad Oncology SA C9

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Celyad Oncology SA reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net309.0K EUR2 Dec 31, 20223.2M EUR2 Dec 31, 2021−90.5%
Operating-lease assets (leased space)223.0K EUR2 Dec 31, 20222.2M EUR2 Dec 31, 2021−89.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents12.4M EUR2 Dec 31, 202230.0M EUR2 Dec 31, 2021−58.5%

Former names

  • CELYAD S.A.Apr 28, 2015 to May 7, 20203
  • CARDIO3 BIOSCIENCES S.A.Mar 31, 2015 to Mar 31, 20153

Filings

55 filings to the SEC since October 2021: 2 annual reports, 3 large holders, 50 other. The latest 20:

  1. Feb 9, 202415F-12B EDGAR
  2. Jan 17, 20246-K EDGAR
  3. Dec 21, 20236-K EDGAR
  4. Dec 18, 20236-K EDGAR
  5. Dec 4, 20236-K EDGAR
  6. Dec 4, 20236-K EDGAR
  7. Nov 24, 20236-K EDGAR
  8. Nov 21, 20236-K EDGAR
  9. Nov 21, 20236-K EDGAR
  10. Nov 15, 20236-K EDGAR
  11. Oct 27, 20236-K EDGAR
  12. Sep 26, 20236-K EDGAR
  13. Sep 22, 20236-K EDGAR
  14. Sep 18, 20236-K EDGAR
  15. Sep 13, 20236-K EDGAR
  16. Sep 11, 20236-K EDGAR
  17. Sep 6, 20236-K EDGAR
  18. Sep 5, 2023SC 13D/A SCHEDULE 13D, AMENDMENT NO. 2 EDGAR
  19. Sep 5, 20236-K EDGAR
  20. Aug 25, 20236-K EDGAR

The 55 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Celyad Oncology SA is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCelyad Oncology SA1
  • CIK0001637890
  • Filer statusNon-accelerated filer1
  • Incorporated inBelgium1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressRue Edouard Belin 12, Mont-Saint-Guibert, C9 14351
  • Phone32 10 394 1001
  • Shares outstanding22,593,956 as of Dec 31, 20222
  • On EDGAR sinceMar 31, 20151
  • Filings230 in all: 6-K (164), CORRESP (10), UPLOAD (10), 20-F (8), 424B5 (6), EFFECT (4), 424B3 (2), F-1/A (2)1
    All 29 form types

    F-3 (2), SC 13D/A (2), SC 13G/A (2), 15F-12B (1), 25-NSE (1), 424B4 (1), 6-K/A (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DRS (1), DRS/A (1), DRSLTR (1), F-1 (1), F-1MEF (1), F-3/A (1), F-6 (1), FWP (1), S-8 (1), SC 13D (1), SC 13G (1)

  • Latest filingsAnnual report (20-F) Mar 23, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10